OTC Monograph Reform: Deemed Final Orders

OTC Monograph Reform: OMOR Format and Content & Electronic SubmissionsПодробнее

OTC Monograph Reform: OMOR Format and Content & Electronic Submissions

OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2021 User FeesПодробнее

OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2021 User Fees

OTC Monograph Reform Overview of Draft Guidance for Formal MeetingsПодробнее

OTC Monograph Reform Overview of Draft Guidance for Formal Meetings

OTC Monograph Regulations Part 1 of 5Подробнее

OTC Monograph Regulations Part 1 of 5

Prescription handover - Community Pharmacy PracticeПодробнее

Prescription handover - Community Pharmacy Practice

Modernizing FDA’s Regulationof Over-the-Counter DrugsПодробнее

Modernizing FDA’s Regulationof Over-the-Counter Drugs

CDER’s Role in Public Health Emergency Response and Medical Countermeasure DevelopmentПодробнее

CDER’s Role in Public Health Emergency Response and Medical Countermeasure Development

What is the Over-the-Counter (OTC) Drug Monograph Process?Подробнее

What is the Over-the-Counter (OTC) Drug Monograph Process?

Monograph reform is here! Learn what to expect and how to prepare.Подробнее

Monograph reform is here! Learn what to expect and how to prepare.

OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2023 User Fees and RegistrationПодробнее

OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2023 User Fees and Registration

TMF Week 2024 - Day 1 - PANEL: Lessons from the Frontlines: Mastering Regulatory Inspections in 2024Подробнее

TMF Week 2024 - Day 1 - PANEL: Lessons from the Frontlines: Mastering Regulatory Inspections in 2024

How Long Do Boosters Take to Offer a Benefit? – Just a Minute! with Dr. Peter MarksПодробнее

How Long Do Boosters Take to Offer a Benefit? – Just a Minute! with Dr. Peter Marks

Health Hearing on Modernizing FDA’s Regulation of Over the Counter Drugs (09/13/2017)Подробнее

Health Hearing on Modernizing FDA’s Regulation of Over the Counter Drugs (09/13/2017)

Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advanced/Recurrent Endometrial CancerПодробнее

Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advanced/Recurrent Endometrial Cancer

Reporting Drug Amount Under Section 510(j)(3) of the FD&C Act – Session 3 and Closing RemarksПодробнее

Reporting Drug Amount Under Section 510(j)(3) of the FD&C Act – Session 3 and Closing Remarks

Decision support for precision oncology: Evolving from monotherapy to genomically informed combi...Подробнее

Decision support for precision oncology: Evolving from monotherapy to genomically informed combi...

RECOURSE Trial: Phase III trial: The Onset of Neutropenia as a Treatment Response IndicatorПодробнее

RECOURSE Trial: Phase III trial: The Onset of Neutropenia as a Treatment Response Indicator

The Food and Drug Omnibus Reform ActПодробнее

The Food and Drug Omnibus Reform Act

Nonprescription Drug Product with an Additional Condition for Nonprescription UseПодробнее

Nonprescription Drug Product with an Additional Condition for Nonprescription Use